Table 3.
Patient Baseline Variable Distribution and Bivariate Correlation With Isolate Susceptibility to Antimicrobial Dispensed at Index
| Baseline Variables | Study Cohort | Isolate Susceptibility to Initially Dispensed Antimicrobial | ||
|---|---|---|---|---|
| Susceptible | Not Susceptible | P Value | ||
| N (%) | n (%) | n (%) | ||
| Overall | 2366 (100.0) | 1908 (80.6) | 458 (19.4) | |
| Escherichia coli | … | … | … | <.0001 |
| No | 508 (21.5) | 370 (19.4) | 138 (30.1) | |
| Yes | 1858 (78.5) | 1538 (80.6) | 320 (69.9) | |
| Age Group, Years | … | … | … | .0010 |
| 12–17 | 100 (4.2) | 77 (4.0) | 23 (5.0) | |
| 18–24 | 379 (16.0) | 326 (17.1) | 53 (11.6) | |
| 25–50 | 851 (36.0) | 702 (36.8) | 149 (32.5) | |
| >50 | 1036 (43.8) | 803 (42.1) | 233 (50.9) | |
| Prior ESBL+ Isolates | … | … | … | .0014 |
| 0–90 days | 24 (1.0) | 15 (0.8) | 9 (2.0) | |
| 91–360 days | 34 (1.4) | 21 (1.1) | 13 (2.8) | |
| No prior AMR | 2308 (97.5) | 1872 (98.1) | 436 (95.2) | |
| Prior FQ-NS Isolates | … | … | … | .0002 |
| 0–90 days | 65 (2.7) | 40 (2.1) | 25 (5.5) | |
| 91–360 days | 91 (3.8) | 70 (3.7) | 21 (4.6) | |
| No prior AMR | 2210 (93.4) | 1798 (94.2) | 412 (90.0) | |
| Prior SXT-NS Isolates | … | … | … | .0003 |
| 0–90 days | 79 (3.3) | 53 (2.8) | 26 (5.7) | |
| 91–360 days | 100 (4.2) | 71 (3.7) | 29 (6.3) | |
| No prior AMR | 2187 (92.4) | 1784 (93.5) | 403 (88.0) | |
| Prior NFT-NS Isolates | … | … | … | .0245 |
| 0–90 days | 65 (2.7) | 48 (2.5) | 17 (3.7) | |
| 91–360 days | 95 (4.0) | 68 (3.6) | 27 (5.9) | |
| No prior AMR | 2206 (93.2) | 1792 (93.9) | 414 (90.4) | |
| Prior Positive Urine Culture | … | … | … | .0947 |
| 0–90 days | 274 (11.6) | 208 (10.9) | 66 (14.4) | |
| 91–360 days | 339 (14.3) | 272 (14.3) | 67 (14.6) | |
| No prior positive urine culture | 1753 (74.1) | 1428 (74.8) | 325 (71.0) | |
| Prior Negative Urine Culture | … | … | … | .0410 |
| 0–90 days | 108 (4.6) | 79 (4.1) | 29 (6.3) | |
| 91–360 days | 133 (5.6) | 101 (5.3) | 32 (7.0) | |
| No prior negative urine culture | 2125 (89.8) | 1728 (90.6) | 397 (86.7) | |
| Prior Oral Abx (Any) | … | … | … | <.0001 |
| 0–90 days | 708 (29.9) | 526 (27.6) | 182 (39.7) | |
| 91–360 days | 572 (24.2) | 454 (23.8) | 118 (25.8) | |
| No prior PO Abx dispensed | 1086 (45.9) | 928 (48.6) | 158 (34.5) | |
| Prior Hospitalization | … | … | … | .0563 |
| 0–90 days | 89 (3.8) | 67 (3.5) | 22 (4.8) | |
| 91–360 days | 313 (13.2) | 240 (12.6) | 73 (15.9) | |
| No prior hospitalization | 1964 (83.0) | 1601 (83.9) | 363 (79.3) | |
Abbreviations: Abx, antibiotic; AMR, antimicrobial resistance; ESBL+, extended-spectrum beta-lactamase producing; FQ, fluoroquinolone; NFT, nitrofurantoin; NS, not susceptible; PO, oral; SXT, trimethoprim-sulfamethoxazole.